Forte Biosciences (FBRX) Enterprise Value (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Enterprise Value of -$58.2 million for Q1 2026, down 26.92% year-over-year from -$79.6 million in Q1 2025, and up 24.37% quarter-over-quarter from -$77.0 million in Q4 2025.
Forte Biosciences (FBRX) Enterprise Value (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Enterprise Value for 11 consecutive years, with -$58.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 26.92% year-over-year to -$58.2 million; the TTM figure through Mar 2026 stood at -$58.2 million (down 26.92% YoY), while the FY2025 annual figure was -$77.0 million, down 31.85% from the prior year.
- Enterprise Value rose to -$58.2 million in Q1 2026 per FBRX's latest filing, from -$77.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$16.4 million in Q3 2024 and bottomed at -$106.1 million in Q2 2025.
- Historically, Enterprise Value has averaged -$48.4 million across 5 years, with a median of -$41.1 million in 2022.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 64.49% — and 2025, when it tumbled 469.51%.
- Forte Biosciences' Enterprise Value stood at -$41.1 million in 2022, then rose by 9.67% to -$37.1 million in 2023, then plunged by 57.21% to -$58.4 million in 2024, then slumped by 31.85% to -$77.0 million in 2025, then advanced by 24.37% to -$58.2 million in 2026.
- Business Quant data shows FBRX's Enterprise Value at -$58.2 million in Q1 2026, -$77.0 million in Q4 2025, and -$93.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -347.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -347.33 Mn |
| Mar 31, 2026 | -58.20 Mn |
| Dec 31, 2025 | -76.96 Mn |
| Sep 30, 2025 | -93.40 Mn |
| Jun 30, 2025 | -106.10 Mn |
| Mar 31, 2025 | -45.86 Mn |
| Dec 31, 2024 | -58.37 Mn |
| Sep 30, 2024 | -16.40 Mn |
| Jun 30, 2024 | -24.50 Mn |
| Mar 31, 2024 | -30.44 Mn |
| Dec 31, 2023 | -37.13 Mn |
| Sep 30, 2023 | -46.19 Mn |
| Jun 30, 2023 | -30.43 Mn |
| Mar 31, 2023 | -35.90 Mn |
| Dec 31, 2022 | -41.10 Mn |
| Sep 30, 2022 | -44.05 Mn |
| Jun 30, 2022 | -38.50 Mn |
| Mar 31, 2022 | -40.04 Mn |
| Dec 31, 2021 | -42.04 Mn |
| Sep 30, 2021 | -45.67 Mn |